#Leqembi

2 stories

Clinical Trials July 14, 2026 · View digest

Eisai and Biogen Present LEQEMBI (Lecanemab) Real-World LEADER Study Data at AAIC 2026 on Tuesday July 14: A Comprehensive Multicenter Retrospective Study of 432 Early Alzheimer's Disease Patients From Diverse US Clinical Settings Who Received at Least Seven LEQEMBI Infusions as of May 2026 Showed 75.9% of Patients Remained Stable and 6.6% Improved Over an Average of 17 Months of Treatment, 87% Chose to Remain on Treatment, and Results Were Consistent Across Sex, Race, Ethnicity, and APOE Genotype

Eisai and Biogen announced Tuesday July 14, 2026 that data from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study, presented at AAIC 2026 in London during the Developing Topics Session '#3-33-DEV-A: Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings,' documented durable clinical outcomes with LEQEMBI in early Alzheimer's disease. The analysis included 432 early Alzheimer's disease patients from diverse US clinical settings who had received at least seven LEQEMBI infusions as of May 2026. Over an average of 17 months of treatment, 75.9% of patients remained clinically stable and 6.6% improved (moving from mild Alzheimer's disease dementia to mild cognitive impairment due to Alzheimer's disease). 87% of patients chose to remain on LEQEMBI treatment. Results were consistent across sex, race, ethnicity, and APOE genotype, supporting long-term benefits of continuous treatment outside of a controlled clinical trial setting.

Clinical Trials July 12, 2026 · View digest

Eisai and Biogen Present LEQEMBI (Lecanemab) Subcutaneous Autoinjector Clinical Data at AAIC 2026 Sunday July 12 Developing Topics Session 'Lecanemab Subcutaneous Formulation in Early Alzheimer's Disease': Efficacy and Safety Comparable to Intravenous Administration Support a Fully Subcutaneous Treatment Pathway From Initiation Through Maintenance in Early Alzheimer's Disease, With Long-Term Use, Maintenance Dosing, and At-Home Administration Data

Eisai and Biogen announced Sunday July 12, 2026 that new clinical data presented at AAIC 2026 in London support that the LEQEMBI (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration in people with early Alzheimer's disease. Data were featured during the Developing Topics Session titled 'Lecanemab Subcutaneous Formulation in Early Alzheimer's Disease: Emerging Clinical Evidence and Practical Use Considerations,' covering the SC formulation, long-term use across diverse patient groups, maintenance dosing, and at-home administration. The findings support a fully subcutaneous treatment pathway from initiation through maintenance treatment, offering greater convenience and flexibility for patients and care partners. The FDA approved Eisai's Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025; the SC autoinjector data at AAIC 2026 extends that framework to initial treatment and long-term dosing. Lecanemab is a humanized IgG1 monoclonal antibody selective for amyloid protofibrils; the July 12 dataset is peptide-adjacent to the broader biologic-CNS delivery coverage.